



NanoEcho strengthens its position through an agreement with Clinical Trial Consultants for the upcoming clinical phase

NanoEcho announces today that the company has entered an agreement with Clinical Trial Consultants (CTC), who will contribute with expertise, guidance, and preparatory activities for the upcoming clinical registration study.

CTC is a Clinical Research Organization (CRO) and thereby specialised in planning, executing, and reporting clinical studies. The agreement means that CTC will provide expertise and guidance during the initial phase of planning and preparations for NanoEcho's upcoming clinical registration study. This agreement constitutes a significant part of the clinical preparations.

"The signed agreement marks a substantial milestone in the preparations for the upcoming clinical registration study. Through this agreement with CTC, we will benefit from their specialised expertise and position ourselves well for our clinical phase", says Linda Persson, CEO of NanoEcho.

For further information, please contact:

Kristina Hallström, CMO & CCO
email: ir@nanoecho.se

NanoEcho develops a new technology for clearer diagnostics of, in the first indication, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern patented ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simple, and cost-effective diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalised treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se